Drawdown of Tranche 3 under the Convertible Note Facility
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) (“Paradigm” or “the Company”) a late-stage drug development company focused on delivering new therapies to address unmet medical needs, advises that it has completed the drawdown of Tranche 3, valued at US$5 million (approximately A$7.6 million), under its US$27 million (A$41.2 million) Convertible Note Facility with Obsidian Global Partners, LLC. The Tr
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Published Canine Study Strengthens iPPS Phase 3 Rationale
- Oral OA Animal Therapy Progresses via AVet Deal
- December 2025 Quarterly Activities Report & Appendix 4C
- iPPS Phase 2 Biomarker Results Published in Leading Journal
- Phase 3 Knee OA Trial Recruitment Update
Later from Paradigm Biopharmaceuticals
- Appendix 4D and Half Year Report
- Paradigm Achieves 50% Patient Dosing in Phase 3
- Upsized $14M Placement Extends Runway Post IA
- March 2026 Quarterly Activities Report & Appendix 4C
- DSMB 20% Review Supports Phase 3, Moldova Activated
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals